Chengdu, China
December 20, 2018
HitGen Ltd announced that the company has entered into a research collaboration with the Crop Science division of Bayer to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Bayer research endeavours. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Bayer. Specific financial details were not disclosed.
“We are delighted to enter this collaboration with Bayer, a global leader in finding solutions for enabling sustainable agriculture. This collaboration further emphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry, and extends the application of the technology into the science of crop protection. We will work closely with Bayer scientists to generate new lead compounds for their research programmes to develop new solutions to agricultural challenges.” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.
“Our research and development (R&D) platforms are supplemented by what we call an ‘open innovation’ model,” said Axel Trautwein, Head of Small Molecules, Crop Science division of Bayer. “HitGen’s experience in DNA-encoded chemistry fits that model well, and we look forward to using their advanced technology platform to develop solutions that help farmers control existing crop threats and get ahead of emerging ones.”
About HitGen Ltd
HitGen is a rapidly growing biotech company with headquarters and main research facilities based in Chengdu, China and with offices in the USA. HitGen has established a platform for small molecular discovery centred around DNA the design, assembly and interrogation of encoded chemical libraries (DELs). HitGen’s DELs contain more than 300 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in Asia, North America, Africa and Europe to discover and develop approaches for novel medicines and agrochemical solutions.
成都先导与拜耳（Bayer）签订 基于DNA编码化合物库技术的新药研发合作协议
为全球农业从事者提供创新作物保护解决方案
中国成都2018年12月20日 成都先导药物开发有限公司（以下简称“成都先导”）今日宣布与拜耳旗下作物科学事业部达成新药研发合作，以期针对拜耳关注的靶点发现全新结构的小分子化合物。基于此协议，成都先导将充分利用以DNA编码化合物库（DNA Encoded Library,以下简称“DEL”）设计、合成及筛选为核心的先进技术平台为拜耳筛选新的先导化合物。依据协议,成都先导将收到首付款及后续里程碑款，具体金额未被批露。
成都先导董事长兼首席执行官李进博士表示“拜耳是一家世界级创新型企业，致力于为可持续农业发展提供创新型保护解决方案，我们非常高兴能与拜耳建立合作。此次合作进一步巩固了成都先导在快速发展的DEL技术领域的地位，同时延伸了DEL技术在作物保护领域的应用研究。我们将与拜耳的科学家们紧密合作，共同发现全新的先导化合物，进一步提供全新的作物保护解决方案，以应对农业挑战，推动农业的未来发展。”
拜耳作物科学事业部小分子研发负责人Alex Trautwein先生表示“成都先导的DEL技术恰好与拜耳以‘Open Innovation’模式为辅的研发平台完美切合。我们非常期待通过先导的技术平台开发创新的解决方案，帮助农业从事者降低现有作物面临的威胁，促进农业发展。”
关于成都先导
成都先导是一家从事新药研发的快速发展的生物技术公司，总部位于中国成都，在美国设有子公司。成都先导已建立了一个以DNA为核心的小分子新药发现平台，即DNA编码化合物库设计合成与筛选技术平台。目前，公司基于数百种不同的骨架结构，已经完成逾三千亿结构全新、具有多样性和类药性DNA编码化合物的合成，并且已有多个案例证实了其针对已知靶点和新兴靶点筛选苗头化合物的能力。成都先导业务遍布亚洲、北美、非洲及欧洲，现已与多家国际大药物公司、生物技术公司、化学公司、基金会以及科研机构建立合作，致力于发现、开发新药及农用化学解决方案。
Topics
Species
